Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Future role of CAR-T in AML

Sascha Haubner, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, comments on the future role of chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of acute myeloid leukemia (AML). In particular, Dr Haubner highlights the need to improve manufacturing and manage toxicities. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.


Sascha Haubner, MD, has received research support from Takeda Pharmaceutical Company Ltd.